Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World data registry aims to map best treatment paths for advanced colorectal cancer

NCT ID NCT04867525

Knowledge-focused Sponsor: iOMEDICO AG Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This registry tracks adults with metastatic colorectal cancer who are starting their first systemic therapy. Researchers will collect information on the treatments doctors choose, how well they work, and patients' quality of life. The goal is to understand what happens in everyday medical practice, beyond controlled clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this registry could reveal which treatment sequences work best in everyday practice, helping doctors make more informed decisions for patients with metastatic colorectal cancer.
What could go wrong
As an observational registry, it does not test a new treatment, so it cannot prove cause and effect. Results may be influenced by patient selection and real-world variability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

500 people

The number who actually took part.

Started

May 2021

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with metastatic (stage IV) colorectal cancer requiring palliative systemic first-line therapy

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with histologically proven metastatic colorectal cancer (stage IV) at time of inclusion (patients with metastatic disease and potential curative treatment intention are allowed) * Age ≥ 18 years * Planned first systemic therapy for metastatic disease * Signed and dated informed consent form * Patients participating in the PRO module: prior to or at start of first systemic treatment for mCRC * Patients not participating in the PRO module: within four weeks after start of fist systemic therapy for mCRC Exclusion Criteria: * Patient who do not receive any systemic therapy for mCRC * Patients whose metastatic disease was surgically resected prior to inclusion and who start adjuvant chemotherapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal cancer metastatic are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal cancer metastatic

Contacts and locations

Locations

  • Multiple sites all over germany

    Multiple Locations, Germany, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.